These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8593206)

  • 1. Osteocalcin expression in primary bone tumors--in situ hybridization and immunohistochemical study.
    Park YK; Yang MH; Kim YW; Park HR
    J Korean Med Sci; 1995 Aug; 10(4):263-8. PubMed ID: 8593206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the presence of osteocalcin, S-100 protein, and proliferating cell nuclear antigen in cells of various types of osteosarcomas.
    Chano T; Matsumoto K; Ishizawa M; Morimoto S; Hukuda S; Okabe H; Kato H; Fujino S
    Eur J Histochem; 1996; 40(3):189-98. PubMed ID: 8922947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological and immunohistochemical diversities, and proliferative activity and grading in osteosarcomas.
    Hasegawa T; Hirose T; Seki K; Hizawa K; Ishii S; Wakabayashi J
    Cancer Detect Prev; 1997; 21(3):280-7. PubMed ID: 9167046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of osteonectin for differential diagnosis of osteogenic bone tumors: an immunohistochemical and in situ hybridization approach.
    Park YK; Yang MH; Park HR
    Skeletal Radiol; 1996 Jan; 25(1):13-7. PubMed ID: 8717113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Submicroscopic and immunohistochemical profile of surface osteosarcomas.
    Franchi A; Comin CE; Santucci M
    Ultrastruct Pathol; 1999; 23(4):233-40. PubMed ID: 10503742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high-grade osteosarcomas.
    Franchi A; Arganini L; Baroni G; Calzolari A; Capanna R; Campanacci D; Caldora P; Masi L; Brandi ML; Zampi G
    J Pathol; 1998 Jul; 185(3):284-9. PubMed ID: 9771482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteosarcoma with epithelioid features. An immunohistochemical study.
    Hasegawa T; Shibata T; Hirose T; Seki K; Hizawa K
    Arch Pathol Lab Med; 1993 Mar; 117(3):295-8. PubMed ID: 7680195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypic heterogeneity in osteosarcomas.
    Hasegawa T; Hirose T; Kudo E; Hizawa K; Usui M; Ishii S
    Hum Pathol; 1991 Jun; 22(6):583-90. PubMed ID: 1864588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteocalcin and osteonectin immunoreactivity in the diagnosis of osteosarcoma.
    Fanburg JC; Rosenberg AE; Weaver DL; Leslie KO; Mann KG; Taatjes DJ; Tracy RP
    Am J Clin Pathol; 1997 Oct; 108(4):464-73. PubMed ID: 9322601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vimentin, osteocalcin and osteonectin expression in canine primary bone tumors: diagnostic and prognostic implications.
    Amaral CB; Leite JDS; Fonseca ABM; Ferreira AMR
    Mol Biol Rep; 2018 Oct; 45(5):1289-1296. PubMed ID: 30066297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.
    Shooshtarizadeh T; Rahimi M; Movahedinia S
    Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteocalcin and osteonectin immunoreactivity in extraskeletal osteosarcoma: a study of 28 cases.
    Fanburg-Smith JC; Bratthauer GL; Miettinen M
    Hum Pathol; 1999 Jan; 30(1):32-8. PubMed ID: 9923924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone.
    Ueda Y; Dockhorn-Dworniczak B; Blasius S; Mellin W; Wuisman P; Böcker W; Roessner A
    J Cancer Res Clin Oncol; 1993; 119(3):172-8. PubMed ID: 8418091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical study of bone GLA protein in primary bone tumors.
    Iwasaki R; Yamamuro T; Kotoura Y; Okumura H; Kasai R; Nakashima Y
    Cancer; 1992 Aug; 70(3):619-24. PubMed ID: 1320449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of β-catenin expression in the differential diagnosis of osteosarcoma, osteoblastoma, and chondroblastoma.
    Erdogan KE; Pacheco M; Gambarotti M; Magagnoli G; Sbaraglia M; Frisoni T; Righi A; Dei Tos AP
    Virchows Arch; 2021 Sep; 479(3):529-535. PubMed ID: 33511430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KPNA2 expression is a potential marker for differential diagnosis between osteosarcomas and other malignant bone tumor mimics.
    Jiang L; Liu J; Wei Q; Wang Y
    Diagn Pathol; 2020 Nov; 15(1):135. PubMed ID: 33176814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of immunohistochemical cyclo-oxygenase-2 (COX-2) and osteocalcin in differentiating between osteoblastomas and osteosarcomas.
    El-Badawi ZH; Muhammad EM; Noaman HH
    Malays J Pathol; 2012 Jun; 34(1):15-23. PubMed ID: 22870593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and beta-catenin, Sox9, and osteocalcin immunostaining of 22 cases.
    Fanburg-Smith JC; Auerbach A; Marwaha JS; Wang Z; Rushing EJ
    Hum Pathol; 2010 May; 41(5):653-62. PubMed ID: 20138330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study.
    Oda Y; Naka T; Takeshita M; Iwamoto Y; Tsuneyoshi M
    Hum Pathol; 2000 Jun; 31(6):709-16. PubMed ID: 10872665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro.
    Garnero P; Grimaux M; Seguin P; Delmas PD
    J Bone Miner Res; 1994 Feb; 9(2):255-64. PubMed ID: 8140939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.